HK1221653A1 - 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統 - Google Patents

用於呼吸遞送三種或更多種活性劑的組合物、方法和系統

Info

Publication number
HK1221653A1
HK1221653A1 HK16109865.5A HK16109865A HK1221653A1 HK 1221653 A1 HK1221653 A1 HK 1221653A1 HK 16109865 A HK16109865 A HK 16109865A HK 1221653 A1 HK1221653 A1 HK 1221653A1
Authority
HK
Hong Kong
Prior art keywords
compositions
systems
methods
active agents
respiratory delivery
Prior art date
Application number
HK16109865.5A
Other languages
English (en)
Inventor
Reisner Colin
Fitzgerald Darken Patrick
Lechuga-Ballesteros David
B Joshi Vidya
Kumar Dwivedi Sarvajna
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of HK1221653A1 publication Critical patent/HK1221653A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16109865.5A 2013-05-22 2016-08-17 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統 HK1221653A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361826424P 2013-05-22 2013-05-22
PCT/US2014/039234 WO2014190204A1 (en) 2013-05-22 2014-05-22 Compositions, methods & systems for respiratory delivery of three or more active agents

Publications (1)

Publication Number Publication Date
HK1221653A1 true HK1221653A1 (zh) 2017-06-09

Family

ID=50942948

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16109865.5A HK1221653A1 (zh) 2013-05-22 2016-08-17 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統
HK16109866.4A HK1221654A1 (zh) 2013-05-22 2016-08-17 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16109866.4A HK1221654A1 (zh) 2013-05-22 2016-08-17 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統

Country Status (20)

Country Link
US (1) US20150150787A1 (zh)
EP (1) EP2999460A1 (zh)
JP (1) JP2016519160A (zh)
KR (1) KR20160013134A (zh)
CN (1) CN105392471A (zh)
AU (1) AU2014268482A1 (zh)
BR (1) BR112015028964A2 (zh)
CA (1) CA2912927A1 (zh)
CL (1) CL2015003422A1 (zh)
CR (1) CR20150645A (zh)
DO (1) DOP2015000284A (zh)
HK (2) HK1221653A1 (zh)
MX (1) MX2015016058A (zh)
NI (1) NI201500163A (zh)
PE (1) PE20160155A1 (zh)
PH (1) PH12015502593A1 (zh)
RU (1) RU2015154720A (zh)
SG (1) SG11201509543YA (zh)
WO (1) WO2014190204A1 (zh)
ZA (1) ZA201509016B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580315C3 (ru) 2009-05-29 2021-06-18 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
RU2665841C2 (ru) * 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EA201691068A1 (ru) * 2013-11-22 2016-09-30 Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк. Ингалируемое лекарственное средство
LT3191081T (lt) 2014-09-09 2020-07-10 Vectura Limited Vaisto forma, apimanti glikopiroliatą, būdas ir aparatūra
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2020123057A2 (en) * 2018-10-31 2020-06-18 Repurposed Therapeutics, Inc. Dba Defender Treatment of exposure to chlorine gas with scopolamine
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN111617138A (zh) * 2020-07-07 2020-09-04 上海凯宝药业股份有限公司 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用
MX2024000468A (es) * 2021-07-09 2024-04-05 Astrazeneca Pharmaceuticals Lp Composiciones, metodos y sistemas para la administracion de farmacos en aerosol.
CN118414148A (zh) * 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (zh) 1972-05-19 1975-08-18 Bofors Ab
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
CA2218074C (en) 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
PT102343B (pt) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
ES2343124T3 (es) 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
AU2004251623B2 (en) 2003-05-28 2010-03-18 Novartis Ag Spray drying of an alcoholic aqueous solution for the manufacture of a water-in-soluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
RU2580315C3 (ru) * 2009-05-29 2021-06-18 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MX2013009525A (es) * 2011-02-17 2013-10-01 Cipla Ltd Combinacion de glicopirrolato y un beta2-agonista.
MX2013013440A (es) * 2011-05-17 2014-06-05 Pearl Therapeutics Inc Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.

Also Published As

Publication number Publication date
HK1221654A1 (zh) 2017-06-09
CN105392471A (zh) 2016-03-09
SG11201509543YA (en) 2015-12-30
DOP2015000284A (es) 2016-04-29
NI201500163A (es) 2016-01-06
ZA201509016B (en) 2018-07-25
BR112015028964A2 (pt) 2017-07-25
AU2014268482A1 (en) 2016-01-07
US20150150787A1 (en) 2015-06-04
CR20150645A (es) 2016-02-10
RU2015154720A (ru) 2017-06-27
EP2999460A1 (en) 2016-03-30
WO2014190204A1 (en) 2014-11-27
JP2016519160A (ja) 2016-06-30
KR20160013134A (ko) 2016-02-03
CA2912927A1 (en) 2014-11-27
MX2015016058A (es) 2016-12-20
PE20160155A1 (es) 2016-04-01
PH12015502593A1 (en) 2016-02-29
CL2015003422A1 (es) 2016-09-02

Similar Documents

Publication Publication Date Title
HK1221654A1 (zh) 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統
IL289736A (en) Provision, use and therapeutic applications of crispr-cas genetic editing systems and genetic editing preparations
IL273507A (en) Methods, devices and systems for administering active substances through the lungs
ZA202003200B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
IL243196A0 (en) Provision and use of cas-crispr systems, vectors and preparations for targeting the liver and treatment
EP3160565A4 (en) Methods, devices and systems for pulmonary delivery of active agents
EP3160554A4 (en) Methods, devices and systems for pulmonary delivery of active agents
PH12016501122A1 (en) Delayed release compositions of linaclotide
EP2841138A4 (en) AEROSOL LABELING SYSTEMS, COMPOSITIONS AND METHOD
ZA201601543B (en) Delivery system for active agents
HK1223583A1 (zh) 透皮釋放活性物質的系統
GB2507357B (en) Agent based application reputation system for operating systems
IL242545B (en) Compositions and methods for administering hydrophobic active substances
PL2961822T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
HK1208188A1 (zh) 用於活性成分遞送的配製物
PL2989192T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
EP3037091A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
EP2996612A4 (en) Antiseptic delivery system
EP2903676A4 (en) CONFIGURATION OF FACIAL MASK, SYSTEM CONTAINING THE SAME AND USE THEREOF IN SUBSTANCE ADMINISTRATION
HUE049663T2 (hu) Gyógyszerbejuttató rendszer egy vagy több aktív összetevõhöz
EP2952204A4 (en) PHARMACEUTICAL COMPOSITION FOR REDUCING OR INHIBITING SCALING FORMATION, CONTAINING BMP-7 AND DILUTION AGENT